Arvinas Inc ARVN:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:00 PM EDT
41.28UNCH (UNCH)
Volume
48,672
Close
41.28quote price arrow down-0.05 (-0.12%)
Volume
475,686
52 week range
13.57 - 53.08
Loading...
  • Open41.71
  • Day High41.98
  • Day Low40.84
  • Prev Close41.33
  • 52 Week High53.08
  • 52 Week High Date02/16/24
  • 52 Week Low13.57
  • 52 Week Low Date10/27/23

Key Stats

  • Market Cap2.811B
  • Shares Out68.08M
  • 10 Day Average Volume0.90M
  • Dividend-
  • Dividend Yield-
  • Beta1.95
  • YTD % Change0.29

KEY STATS

  • Open41.71
  • Day High41.98
  • Day Low40.84
  • Prev Close41.33
  • 52 Week High53.08
  • 52 Week High Date02/16/24
  • 52 Week Low13.57
  • 52 Week Low Date10/27/23
  • Market Cap2.811B
  • Shares Out68.08M
  • 10 Day Average Volume0.90M
  • Dividend-
  • Dividend Yield-
  • Beta1.95
  • YTD % Change0.29

RATIOS/PROFITABILITY

  • EPS (TTM)-6.50
  • P/E (TTM)-6.35
  • Fwd P/E (NTM)-7.24
  • EBITDA (TTM)-396.70M
  • ROE (TTM)-59.97%
  • Revenue (TTM)78.50M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-464.71%
  • Debt To Equity (MRQ)0.12%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Arvinas Inc

 

Profile

MORE
Arvinas, Inc. is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The Company uses its PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body's own natural protein disposal system...
John Houston Ph.D.
Chairman of the Board, President, Chief Executive Officer
Randy Teel Ph.D.
Interim Chief Financial Officer, Treasurer
Jared Freedberg
General Counsel
Address
5 Science Park
New Haven, CT
06511-1966
United States

Top Peers

SYMBOLLASTCHG%CHG
MRUS
Merus NV
45.03+0.28+0.63%
KYMR
Kymera Therapeutics Inc
40.20+0.03+0.07%
ALPN
Alpine Immune Sciences Inc
39.64+0.99+2.56%
RYTM
Rhythm Pharmaceuticals Inc
43.33+1.54+3.69%
NTLA
Intellia Therapeutics Inc
27.51+0.49+1.81%